



IAS HIV Cure & Cancer Forum

22 & 23 July 2017

Institut Curie, Paris, France

SATURDAY 22 JULY 2017

8h00 – 9h00		Registration
9h00 – 10h00	Opening Session	Welcome and Introduction Françoise Barré-Sinoussi, France Jack Whitescarver, United States
	Keynote	HIV/AIDS and Cancer cure: Is it the same battle? Monsef Benkirane, Institute of Human Genetics, CNRS, France
10h00 – 11h10	Session 1	Burden of Disease Diana Finzi, Division of AIDS, NIAID, NIH, United States Nicolas Chomont, Université de Montréal, CRCHUM, Canada
	Invited speakers	Real time detection of viral replication kinetics: A tool to identify functional viral reservoirs François Villinger, New Iberia Research Center, University of Louisiana at Lafayette, United States Liquid Biopsies: Monitoring the Cancer Genome in Blood Sarah-Jane Dawson, Peter MacCallum Cancer Centre, Australia
	OA1-1	Impact of vorinostat treatment of non-Hodgkin's lymphoma on HIV-1 latent reservoir <i>Adam Capoferri, Johns Hopkins University School of Medicine, United States</i>
	OA1-2	Enrichment of the HIV reservoir in CD32+ CD4 T cells occurs early and is closely associated with immune checkpoint receptor expression <i>Genevieve Martin, University of Oxford, United Kingdom</i>
		General Discussion 10'
11h10 – 11h40		Break

11h40 – 13h00	Session 2	Epigenetic Control of HIV-1 Latency: From Molecular Targets to Cure Strategies Olivier Rohr, University of Strasbourg/ IUT Louis Pasteur, France Rafick-Pierre Sekaly, Case Western Reserve University, United States
	Invited Speakers	Chromatin dynamics – epigenetic parameters and cellular fate Geneviève Almouzni, Institut Curie, France Epigenetic control of HIV latency Jonathan Karn, Case Western Reserve University, United States
	OA2-1	Identification of a new factor involved in DNA methylation-mediated repression of latent HIV-1 <i>Carine Van Lint, Université Libre de Bruxelles (ULB), Belgium</i>
	OA2-2	JAK inhibitors employ novel mechanisms to block reservoir seeding and HIV persistence <i>Christina Gavegnano, Emory University, United States</i>
	OA2-3	Small-Molecule Chemotherapeutic Drugs Reactivate HIV-1 via Non-Canonical Pathways and Modulate CD8 T cell response <i>Isa Munoz-Arias, University of California, San Francisco, United States</i>
		General Discussion 10'

**13h00 –
14h00** **Lunch**

14h00 – 15h20	Session 3	Immunology and Immunotherapy Daniel Douek, VRC, NIAIDS, United States Laurence Weiss, Hôpital Européen Georges Pompidou, France
	Invited Speakers	Paradigm shift in cancer therapy: targeting immune cells rather than cancer cells Aurélien Marabelle, Gustave Roussy, France Epigenetic control of T cell memory differentiation Sebastian Amigorena, Institut Curie, France
	OA3-1	HIV reservoir dynamics and immune responses after anti-PD-1 therapy <i>Timothy J. Henrich, University of California, San Francisco, United States</i>
	OA3-2	PD-1 blockade in 12 HIV-infected patients with lung cancer <i>Brigitte Autran, APHP - Hôpital Pitié Salpêtrière, France</i>

OA3-3	Anti-PD-1 disrupts HIV latency in non-proliferating but not in proliferating T-cells <i>Sharon Lewin, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Australia</i>
	General Discussion 10'

15h20 – 16h30	Session 4	Immune Modulation and HIV Infection José Alcamí, Instituto de Salud, Spain Nina Russell, Bill & Melinda Gates Foundation, United States
	Invited Speakers	Tissue Inflammation profiles: lessons for HIV/SIV control Michaela Muller-Trutwin, Institut Pasteur, France Interferon epsilon regulation of mucosal immune response in infection and cancer Paul Hertzog, Hudson Institute of Medical Research, Australia
	OA4-1	Combined IL-21 and IFN α treatment limits residual inflammation, viral persistence and delays viral rebound in SIV-infected Rhesus macaques <i>Mirko Paiardini, Yerkes National Primate Research Center, Emory University, United States</i>
	OA4-2	Evaluation of Different Treg Depletion Approaches as Strategies for Improved SIV Reactivation and Clearance <i>Ranjit Sivanandham, Center for Vaccine Research, University of Pittsburgh, United States</i>
		General Discussion 10'

16h30 – 18h00

Poster Exhibition & Networking Session

SUNDAY 23 JULY 2017

9h00 – 10h00	Session 5	Gene Therapy Keith Jerome, Fred Hutchinson Cancer Research Center, United States Monique Nijhuis, University Medical Center Utrecht, Netherlands
	Invited Speakers	Fast generation of the T cell compartment by using a ligand of Notch: Possible application to HIV affected patients

		<p>Marina Cavazzana, Hôpital Necker, France</p> <p>Designing CART cells for HIV : a link between cancer and infectious disease therapy Larry Corey, Fred Hutchinson Cancer Research Center, United States</p>
	OA5-1	<p>Achievement of full donor chimerism with episodes of alloreactivity contributes to reduce the HIV reservoir after allogenic stem cell transplantation <i>Maria Salgado, AIDS Research Institute, IrsiCaixa, Spain</i></p> <p>General Discussion 10'</p>
10h00 – 10h30		Break
10h30 – 12h00	Session 6	<p>Clinical Trial Design and Participation</p> <p>Sharon Lewin, The Doherty Institute, University of Melbourne, Australia Olivier Lambotte, APHP – Hôpital Bicêtre, France</p> <p>Panelists Jinatanat Ananworanich, US Military HIV Research Program, United States Michael Louella, University of Washington AIDS Clinical Trials Unit, United States Jean-Philippe Spano, Pitié-Salpêtrière University Hospital, France Gilliosa Spurrier, Mélanome France, France Thomas Uldrick, Center for Cancer Research, NCI, United States</p>
12h00 – 12h30	Closing Session	<p>Steven Deeks, University of California, San Francisco, United States</p> <p>Closing Lecture Antibodies for Tumor Immunotherapy (and HIV?) Alan Korman, Bristol Myers Squibb, United States</p>
12h30 – 12h45		Award Ceremony
12h45 – 13h00		<p>Closing Remarks Françoise Barré-Sinoussi, France Jack Whitescarver, United States</p>